Genomic and transcriptomic landscape of extranodal marginal zone lymphoma

I Izidore S. Lossos (29Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL) L Leo Biral (2Duke University, Darham, United States) D Devang Thakkar (14Data Driven Bioscience, Durham, United States) K Kikkeri N Naresh (2Fred Hutchinson Cancer Center, Seattle, United States) S Sarah Ondrejka (3Cleveland Clinic, Cleveland, United States) E Eric Hsi (3Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, United States) M Mina Xu (1Yale School of Medicine, Hematology/Oncology, New Haven, United States) J Jean Koff (7Winship Cancer Institute, Emory University School of Medicine, Hematology and Medical Oncology, Atlanta, United States) D David Jaye (8Emory, Atlanta, United States) P Peter Nørgaard (9University of Copenhagen, Copenhagen, Denmark) M Marie Fredslund Breinholt (9University of Copenhagen, Copenhagen, Denmark) R Rebecca Leeman-Neill (10Weil Cornell University, New York, United States) J Jennifer Shingleton (1Duke University, Durham, United States) L Lanie Happ (3Data Driven Bioscience, Darham, United States) C Cassandra Love (1Duke University, Durham, United States) E Emily F. Mason (1Vanderbilt University Medical Center, Department of Hematology/Oncology, Nashville, United States) A Abner Louissaint C Choon Kiat Ong C Chee Leong Cheng (10Singapore General Hospital, Singapore, Singapore) R Raju Pillai M Mette Pedersen (From Prehospital Emergency Medical Services, Central Denmark Region (M.F.V., A.L.P., A.H.P., S.W., L.W.F., C.M., K.B.W., A.B., T.H.D., L.K.R., L.R.M., M.L.L., T.E., A.G.N., C.R., L.W.A.), the Department of Clinical Medicine, Aarhus University (M.F.V., A.G., C.J.T., S.C., L.W.A.), and the Departments of Anesthesiology and Intensive Care (A.G., M.J.H., T.H.D., S.C., C.G.N., B.S., L.W.A.), Cardiology (C.J.T.), and Radiology (E.K.), Aarhus University Hospital, Aarhus, the Department of Anesthesiology and Intensive Care, Aalborg University Hospital (T.L.K., F.M.N.), the Center for Prehospital and Emergency Research, Department of Clinical Medicine, Aalborg University and Aalborg University Hospital (E.F.C.), and Emergency Medical Services, North Denmark Region (P.B.), Aalborg, the Prehospital Research Unit (S.M., P.M.H.) and Emergency Medical Services (J.H.H., M.B., L.-G.R.N., M.P., G.K.-A., P.M.H.), Region of Southern Denmark, the Department of Anesthesiology and Intensive Care, Odense University Hospital (J.H...) C C. Cameron Yin (1UT MD Anderson Cancer Center, Hematopoietic Biology and Malignancy, Houston, United States) R Rex Au-Yeung (8University of Hong Kong, Hong Kong, Hong Kong) M Marja-Liisa Karjalainen-Lindsberg (9University of Helsinki, Helsinki, Finland) A Amy Chadburn (6Weill Cornell Medicine, Division of Hematopathology, Department of Pathology and Laboratory Medicine, New York, United States) M Matthew McKinney (23Duke Cancer Institute, Durham, United States) P Payal Sojitra (11Rutgers, Robert Wood Johnson Medical Center, New Brunswick, United States) A Andrew Evans (3University of Rochester Medical Center, Rochester, United States) M Magdalena Czader (19Indiana University, Indianapolis, United States) Y Yan Jiong (18University of Toronto, Toronto, Canada) S Sandeep Dave J Jennifer Chapman (1University of Miami and Sylvester Comprehensive Cancer Center, Pathology, Miami, United States)

Abstract

Abstract Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin B-cell lymphoma accounting for 7-10% of lymphoma diagnoses. Extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT) is the most common subtype (61%) of MZL. While the mutational landscape, chromosomal aberrations and transcriptome of nodal and splenic MZL have been extensively evaluated, the mutational landscape of EMZL has only been evaluated in a small number of patients and mainly by targeted sequencing. Consequently, the comprehensive genomic landscape of EMZL remains largely uncharacterized. Herein, we performed whole exome sequencing followed by targeted sequencing of potential tumor driver genes, copy number and/or RNA transcriptome analyses in 165 patients with pretreatment EMZL tumors involving 16 anatomic locations. All samples were collected and underwent expert review as part of the Atlas of Blood Cancer Genomes consortium. The most common anatomic locations were ocular adnexa (OAMZL) (n=35), gastric (n=25, including 6 positive for Helicobacter pylori), salivary glands (n=25), and lungs (n=24). Using common criteria for variant mutation calling and significant focal copy number (CN), we identified 1218 variants (1030 missense and 188 truncation mutations) across 174 genes and 2837 CN focal alterations (1614 copy gains and 1223 copy number losses). Of these genes, 44 and 11 were mutated in >5% and >10% of specimens, respectively. We detected variants identified previously by targeted sequencing in EMZL from different locations (e.g. TNFAIP3 (A20) (12%), TBL1XR1 (13%), SPEN (10%), CARD11 (7%), TET2 (7%) and CREBBP (6%)). We detected mutations in KLF2 (10 mutations in 8 EMZL patients) and PTPRD (7 mutations in 7 EMZL patients) that were previously suggested to be specific for splenic and nodal MZL, respectively. We also detected variants not previously reported in EMZL, including a transcriptional factor ZEB2, LRP1B,and others. The most frequently mutated gene in our study (25% of tumors) was IGLL5. Some mutations were limited to specific locations (e.g. ZEB2 mutations seen exclusively in gastric and salivary gland EMZL), while most were observed across all anatomic locations. There was no association between specific mutations and clonal IGHV, in contrast to previous reports. Using Enrichr tool, we observed enrichment of mutations in genes belonging to the B cell receptor activation, NOTCH signaling, Wnt-beta catenin signaling, NF-kB signaling , PI3K AKT signaling, DNA repair and other pathways. Chromosomal and copy number changes were also commonly observed including previously reported trisomy of chromosomes 3 and 18. Combining DNA mutations and CN alterations, the number of genetic lesions per tumor sample in the 174 mutated genes ranged from 0 to 95, with an average load of 17 lesions per case. RNA sequencing was successful in 159 EMZL tumors from 16 distinct anatomic locations. Unsupervised clustering using all genes with a median log2-normalized gene expression value greater than 5 and a standard deviation greater than 1 (1323 genes) demonstrated that the majority of gastric EMZL with and without H. pylori infections clustered together on 2 dendrograms as did most of the samples of OAMZL. Since the clustering could be forced by organ-specific and not tumor-specific gene expression, we next focused on the expression of the 345 genes from the LM22 matrix that passed our transcriptomic row filtering. Unsupervised clustering resulted in clustering of most gastric EMZL irrespective of H. pylori positivity together in the same dendrogram branch, accompanied by few additional EMZL from other anatomic locations. Most of the EMZL samples from other locations did not show preferential co-clustering together. On comparison of gene expression between gastric and OAMZL, there was enrichment of the B-cell receptor signaling pathway, B-cell activation, B-cell naïve and B-cell memory cells, B-cell proliferation and NF-kB signaling in the latter. Immune microenvironment analysis showed a statistically significant increase in resting mast cells and decrease in M1 macrophages in gastric EMZL and increase in regulatory T cells in salivary EMZL. The broad genomic studies reported here underscore the biological similarity of EMZL across anatomical sites with the potential exceptions of gastric EMZL (regardless of H. Pylori status). These data provide valuable genomic and transcriptomic resources to inform future diagnostic and therapeutic strategies.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 1761-1761
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (32)

I

Izidore S. Lossos

29Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

L

Leo Biral

2Duke University, Darham, United States

D

Devang Thakkar

14Data Driven Bioscience, Durham, United States

K

Kikkeri N Naresh

2Fred Hutchinson Cancer Center, Seattle, United States

S

Sarah Ondrejka

3Cleveland Clinic, Cleveland, United States

E

Eric Hsi

3Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, United States

M

Mina Xu

1Yale School of Medicine, Hematology/Oncology, New Haven, United States

J

Jean Koff

7Winship Cancer Institute, Emory University School of Medicine, Hematology and Medical Oncology, Atlanta, United States

D

David Jaye

8Emory, Atlanta, United States

P

Peter Nørgaard

9University of Copenhagen, Copenhagen, Denmark

M

Marie Fredslund Breinholt

9University of Copenhagen, Copenhagen, Denmark

R

Rebecca Leeman-Neill

10Weil Cornell University, New York, United States

J

Jennifer Shingleton

1Duke University, Durham, United States

L

Lanie Happ

3Data Driven Bioscience, Darham, United States

C

Cassandra Love

1Duke University, Durham, United States

E

Emily F. Mason

1Vanderbilt University Medical Center, Department of Hematology/Oncology, Nashville, United States

A

Abner Louissaint

C

Choon Kiat Ong

C

Chee Leong Cheng

10Singapore General Hospital, Singapore, Singapore

R

Raju Pillai

M

Mette Pedersen

From Prehospital Emergency Medical Services, Central Denmark Region (M.F.V., A.L.P., A.H.P., S.W., L.W.F., C.M., K.B.W., A.B., T.H.D., L.K.R., L.R.M., M.L.L., T.E., A.G.N., C.R., L.W.A.), the Department of Clinical Medicine, Aarhus University (M.F.V., A.G., C.J.T., S.C., L.W.A.), and the Departments of Anesthesiology and Intensive Care (A.G., M.J.H., T.H.D., S.C., C.G.N., B.S., L.W.A.), Cardiology (C.J.T.), and Radiology (E.K.), Aarhus University Hospital, Aarhus, the Department of Anesthesiology and Intensive Care, Aalborg University Hospital (T.L.K., F.M.N.), the Center for Prehospital and Emergency Research, Department of Clinical Medicine, Aalborg University and Aalborg University Hospital (E.F.C.), and Emergency Medical Services, North Denmark Region (P.B.), Aalborg, the Prehospital Research Unit (S.M., P.M.H.) and Emergency Medical Services (J.H.H., M.B., L.-G.R.N., M.P., G.K.-A., P.M.H.), Region of Southern Denmark, the Department of Anesthesiology and Intensive Care, Odense University Hospital (J.H...

C

C. Cameron Yin

1UT MD Anderson Cancer Center, Hematopoietic Biology and Malignancy, Houston, United States

R

Rex Au-Yeung

8University of Hong Kong, Hong Kong, Hong Kong

M

Marja-Liisa Karjalainen-Lindsberg

9University of Helsinki, Helsinki, Finland

A

Amy Chadburn

6Weill Cornell Medicine, Division of Hematopathology, Department of Pathology and Laboratory Medicine, New York, United States

M

Matthew McKinney

23Duke Cancer Institute, Durham, United States

P

Payal Sojitra

11Rutgers, Robert Wood Johnson Medical Center, New Brunswick, United States

A

Andrew Evans

3University of Rochester Medical Center, Rochester, United States

M

Magdalena Czader

19Indiana University, Indianapolis, United States

Y

Yan Jiong

18University of Toronto, Toronto, Canada

S

Sandeep Dave

J

Jennifer Chapman

1University of Miami and Sylvester Comprehensive Cancer Center, Pathology, Miami, United States